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Abstract
Evidence-based guidelines have undergone an incredible transformation over the last number of years. Significant
advances include explicit linkages of systematic evidence summaries to the strength and direction of recommendations,
consideration of all patient-important factors, transparent reporting of the recommendation generation process including
conflict of interest management strategies and the production of clinical practice guidelines which use simple and clear
language. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology provides a
framework for guideline development and was employed to produce the recently published ATS/ERS/JRS/ALAT update
on treatment for idiopathic pulmonary fibrosis (IPF). Herein we discuss the advantages of using an evidence-based
approach for guideline development using the IPF process and resultant document as an example.
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Background
Evidence-based guidelines have undergone intense
evolution over the last 15 years [1–4]. The main driver
behind this transformation has been the change in focus
from what used to be called expert- or consensus-based
to evidence-driven recommendations. This distinction
represents a typical misunderstanding as even in the
era of evidence-based guidelines, recommendations are
developed by clinical experts in the field and require
consensus of panel members on the best possible treatment
options. It is the transparent link between the evidence and
the recommendations and the requirement of making
structured expert judgments that represents a shift in the
guideline development paradigm. This is true even for
evidence-based guidelines that focus on complex and rare
diseases such as idiopathic pulmonary fibrosis (IPF).
In 2000, a selected panel of international experts in
the field of interstitial lung diseases provided a guideline
for the diagnosis and management of IPF [5]. Due to the
paucity of evidence available and the relatively immature
field of guideline methodology, this document was devel-
oped using the conventional consensus-approach based
on the opinions of the few expert panel members without
a systematic review of the literature or formal quality of
evidence evaluation. Regardless, this document, then
considered state of the art for the disease, provided useful
direction to clinicians in diagnosing and managing pa-
tients with IPF. Over the next decade, an increasing
number of studies in the field of IPF were published
based on this guidance document. With accumulating
evidence, it became onerous for practicing clinicians to
carefully review and interpret the most current studies.
In order to address this challenge and to improve on
the previous document, the 2011 guideline document
employed an evidence-based approach, namely the GRADE
(Grading of Recommendations Assessment, Development
and Evaluation) approach to guideline development [6, 7].
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The 2011 guideline redefined IPF with precise diagnostic
criteria based on clinical, radiological and histopathological
features. Also, for the first time in the field of IPF, it pro-
vided evidence-based treatment recommendations [8].
In this commentary, we will discuss the motivation
behind this evolution in evidence-based guidelines and
the benefits of developing guidelines that are linked to
underlying evidence summaries along with explicit as-
sessments of the quality (certainty) of the evidence. We
will focus on the utility of GRADE methodology [7, 9],
used for the 2011 IPF evidence-based guideline and again
for the more recent 2015 IPF treatment update [10].
Evidence-based Guideline Development
Some believe that the opinion of experts in the field is
driven by their understanding of the clinical problem
and their accurate interpretation of the underlying lit-
erature and therefore such recommendations may be
considered, in effect, evidence-based. This approach
has gone wrong on many occasions [11, 12]. Using a
transparent and structured process in guideline devel-
opment not only mandates a linkage of evidence to
recommendation development but also ensures this
linkage is explicit and systematically demonstrated [13–20].
In effect, this helps to limit the potential for bias. Guideline
panel members may have strong opinions or academic bias
surrounding a specific area in which they have clinical ex-
pertise or they may have other bias related to interactions
with academic colleagues or industry partners [21, 22]. In
an attempt to address this, GRADE requires systematic or
pragmatic searches of the literature and the production of
evidence summaries such as evidence profiles [23], ideally
based on pooled treatment effects and produced by panel
members without conflict of interest (COI) or independent
methodologists. The latter helps to ensure a fair and
reproducible assessment of the current literature address-
ing a specific clinical question [21].
Another significant benefit of evidence-based guidelines
using GRADE methodology is the formal assessment of
certainty in treatment effects (also known as quality of evi-
dence or confidence in evidence). GRADE mandates a sys-
tematic and explicit assessment of specific methodological
domains in order to evaluate how certain we are in the
evidence for each outcome [24]. The certainty in treat-
ment effect is then considered by the guideline panel and
factored into the judgement regarding the strength and
direction of recommendations. In this regard, several
guidelines that followed unstructured approaches have un-
fortunately made inappropriately strong recommendations
without considering the certainty in the evidence. As
an example from the IPF literature, the 2000 consensus
statement recommended treatment with azathioprine
and corticosteroids for patients with IPF without explicit
quality of evidence assessment [5]. Subsequent RCTs have
since demonstrated the harm of this treatment inter-
vention [25].
For the 2015 IPF treatment guideline, the McMaster
University GRADE (MacGRADE; cebgrade.mcmaster.ca)
team performed comprehensive systematic reviews for
each of the 12 clinical questions. These were done in
collaboration with clinical experts in the field to ensure
proper question development and an experienced infor-
mation scientist [26]. These systematic reviews provided
the IPF guideline panel, including experienced IPF experts
(who based on their involvement in IPF clinical trials and
direct financial COI were considered conflicted panel
members) and the non-conflicted members with the best
available evidence summaries on which to base recom-
mendations. The conflicted and non-conflicted members
of the panel discussed all the evidence summaries in an
open format, thereby enabling the non-conflicted panel
members to deepen their understanding of the clinical
relevance of the data and seek clarification as required.
The evidence summaries were included as part of the
guideline document to ensure the transparency of the
entire process.
Certainties in evidence assessments were performed
by the MacGRADE team and were then reviewed by the
entire panel to ensure accuracy and agreement. In each
case that the certainty in effect estimates was downgraded,
explicit rationale was provided in the evidence profile and
in the guideline manuscript. Including the certainty as part
of the final recommendation, as we have done for the
2015 IPF evidence-based guideline, helps stakeholders in
interpreting the recommendations made by the panel.
Recommendations based on higher quality of evidence
allow clinicians and patients to be more reassured that this
intervention is beneficial. Recommendations based on
lower quality of evidence provide caution to stakeholders
and recognize the uncertainty that exists regarding the
benefits of this intervention.
Although the estimate of treatment effect and certainty
in evidence are important, guideline panelists should also
consider other factors when deciding on the strength of
recommendations. Elements such as the balance between
the desirable and undesirable effects, the resources re-
quired, the impact on health equality, the acceptability
and the feasibility of treatment must also be considered
[20]. As opposed to consensus documents that use an
ad hoc approach, GRADE mandates an explicit assess-
ment of these criteria, using the Evidence-to-Decision
framework (EtD), with documentation of panel judgements
and rationale [19, 20, 27].
Input from clinical experts in the field is integral and
guideline panelists must interpret the evidence sum-
mary, the certainty in estimate effects and consider the
factors listed above in order to arrive at a direction and
strength of recommendation using the EtD. Although
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some judgements will require an element of subjectivity,
GRADE ensures explicit recording of rationale in order
to improve transparency and reproducibility. Discussion
of the evidence summaries and other EtD criteria for
the 2015 IPF guidelines included all panel members,
however, in order to help ensure impartiality, only
non-conflicted members of the panel were permitted
to formulate the recommendations themselves [22].
The final result, using the GRADE process, is a compre-
hensive, systematic, and explicit evidence-based guideline.
Recommendations for the 2015 IPF update were formu-
lated using the common terminology of “we suggest”
for conditional (also known as weak) recommendations
and “we recommend” for strong recommendations [19].
Strong recommendations are those that are applicable to
the vast majority of patients, understanding a small minor-
ity will choose the opposite course of action. These recom-
mendations are sometimes used to drive policy decisions.
Conditional recommendations should apply to the majority
of patients but there will be a large minority who will
choose the opposite [13]. For conditional recommenda-
tions, especially those based on low or very low certainty of
evidence, a model of shared decision-making between clini-
cians and patients is imperative considering all the factors
above in addition to the individual patient’s values and pref-
erences [28]. In essence, providing the recommendation in
clear language along with a descriptive rationale empowers
patients, clinicians, and stakeholders to better understand
how the recommendations were formulated and to better
apply them to their specific clinical practices and situations.
This process using GRADE methodology is inherently
different than that used by regulatory agencies when
they consider market approval for pharmacological agents
for the treatment of IPF.
Conclusion
In summary, guidelines lacking the methodological com-
ponents described above, especially those on topics with
sufficient evidence, while conveying the (unstructured)
opinions of clinical experts in the field, have a significant
risk of providing biased recommendations that may be
then used to guide patient care. With the increasing
amount of evidence that has accumulated since the 2000
guidelines, the evolution towards evidence-based guide-
lines using the methodology described for a complex
disease such as IPF is a clear benefit to all and represents
a true advance in clinical science and patient-centered
healthcare. At the end, what arguments can be made
against transparency in guideline development?
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